Literature DB >> 19675369

What's new in the 2009 US guidelines for prevention and treatment of opportunistic infections among adults and adolescents with HIV?

John T Brooks1, Jonathan E Kaplan, Henry Masur.   

Abstract

Despite dramatic declines in the incidence of opportunistic infections (OIs) in the United States, they remain an important cause of morbidity and mortality for HIV-infected persons. Previously separate guidelines on the prevention of OIs and on the treatment of OIs have been combined recently into an updated single document; the present article reviews salient changes to and new information contained in this guidance. Chapters on hepatitis B virus infection and tuberculosis have been expanded substantially, and each chapter now includes information on immune reconstitution inflammatory syndrome. In addition, there is detailed discussion on the role of antiretroviral therapy in OI prevention and issues concerning the initiation of antiretroviral therapy during treatment of an acute OI. In the future, these guidelines will likely be maintained as an internet-based document to facilitate wider dissemination and more rapid updates.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19675369

Source DB:  PubMed          Journal:  Top HIV Med        ISSN: 1542-8826


  2 in total

1.  [Factors associated with non-adherence of adults infected with HIV on antiretroviral therapy in a referral hospital in Douala].

Authors:  Emmanuel Noel Essomba; Dieudonné Adiogo; Danielle Christiane Kedy Koum; Baudouin Amang; Leopold Gustave Lehman; Yves Coppieters
Journal:  Pan Afr Med J       Date:  2015-04-27

2.  The Study of the Prevention of Anal Cancer (SPANC): design and methods of a three-year prospective cohort study.

Authors:  Dorothy A Machalek; Andrew E Grulich; Richard J Hillman; Fengyi Jin; David J Templeton; Sepehr N Tabrizi; Suzanne M Garland; Garrett Prestage; Kirsten McCaffery; Kirsten Howard; Winnie Tong; Christopher K Fairley; Jennifer Roberts; Annabelle Farnsworth; I Mary Poynten
Journal:  BMC Public Health       Date:  2013-10-09       Impact factor: 3.295

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.